Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline Cambridge (UK) based Mission Therapeutics, a clinical-stage biotechnology company developing novel therapeutics that promote the removal of dysfunctional mitochondria to restore cellular health and function, announced the divestment of MTX652, […]
Sofinnova strengthens its growth strategy with a high-caliber London-based Partner Physician-scientist combining frontline clinical experience, health financing and policy expertise, and a proven track record in venture capital Over 20 years in drug development at Bristol Myers Squibb, Eli Lilly, and the Roche Venture Fund as well as in healthcare policy and financing PARIS, France […]
Sofinnova Partners announced Myricx Bio agrees to be acquired by Novartis Sofinnova Partners, a leading European life sciences venture capital firm, announced that its portfolio company Myricx Bio has reached an agreement to be acquired by Novartis for up to $1.5 billion, including $1.1 billion cash upfront plus potential milestone payments. Sofinnova Partners seeded the […]
Sofinnova Partners co-led the seed investment in 2019 and has supported the company from founding through to exit The proposed acquisition combines the oncology expertise of Novartis with Myricx Bio’s novel ADC assets and platform having broad potential across multiple solid tumor types Myricx Bio’s first-in-class NMTi payload platform is designed to improve the therapeutic […]
The World Cup kicked off this week and so did our clients, with new appointments, important clinical trial updates and major collaborations announced! The Optimum team was proud to support and attend Weatherden’s Symposium on Women’s Health yesterday, which featured a stellar line-up of speakers to explore how smarter clinical development and regulatory strategy can […]
